Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.85 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.74 |
| ▸ | JAK3 | P52333 | 1/20 | 0.74 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.72 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.70 |
| ▸ | FLT3 | P36888 | 8/20 | 0.70 |
| ▸ | KIT | P10721 | 5/20 | 0.70 |
| ▸ | FLT4 | P35916 | 5/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.70 |
| ▸ | KDR | P35968 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10091844 | 1.00 | NTRK1 (0.85) | NTRK1TLK2JAK3AURKBNTRK3 | |
| SCHEMBL396901 | 0.92 | NTRK1 (1.00) | NTRK1TLK2JAK3AURKBNTRK3 | |
| SCHEMBL396900 | 0.92 | NTRK1 (1.00) | NTRK1TLK2JAK3AURKBNTRK3 | |
| SCHEMBL397846 | 0.92 | NTRK1 (0.89) | NTRK1TLK2JAK3AURKBNTRK3 | |
| SCHEMBL397847 | 0.92 | NTRK1 (0.89) | NTRK1TLK2JAK3AURKBNTRK3 | |
| SCHEMBL10091847 | 0.92 | NTRK1 (0.89) | NTRK1TLK2JAK3AURKBNTRK3 | |
| SCHEMBL396854 | 0.88 | NTRK1 (0.70) | NTRK1TLK2JAK3AURKBNTRK3 | |
| SCHEMBL10091891 | 0.88 | NTRK1 (0.70) | NTRK1TLK2JAK3AURKBNTRK3 | |
| SCHEMBL398830 | 0.86 | TLK2 (0.89) | NTRK1TLK2JAK3AURKBNTRK3 | |
| SCHEMBL398831 | 0.86 | TLK2 (0.89) | NTRK1TLK2JAK3AURKBNTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | claimed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |